LIPIGO

Patented weight management solution based on brewer's yeast cell wall functional extract with selective fat binding properties.

The scope

– Worldwide obesity has more than doubled since 1980.

– In 2014, more than 1.9 billion adults (+18 years), were overweight. Of these over 600 million were obese [1].

The current approach

A multitude of OTC lipid-lowering dietary supplements are being currently marketed, with advertising claims which may give consumers unrealistic expectations. While they

are advertised to both lower cholesterol and produce rapid weight loss, they can at the same time cause anti-nutritional effects due to their ability to trap also liposoluble molecules which are beneficial for human health (e.g. liposolubles vitamins such as Vitamin A, D, E and K) [2, 3].

The product

(Ingredient protected by patent WO2014001589)

LipiGO was the extract selected from the cell-wall fraction of Saccharomyces cerevisiae having the greatest capacity to reduce fat absorption. A blend of specific beta-glucans and chitin/chitosan polymers with a selective lipid-lowering effect. The origin of the

product is a natural brewer's or baker's yeast extract (non GMO).

The Evidence

An in vivo trial was conducted using twenty-four guinea pigs that were randomly distributed in three groups: LipiGO supplemented group, cellulose supplemented group (negative control) and a commercial control group supplemented with Oat bran. All groups received the products during 4 weeks. A significant increase ($P<0.05$) in total fatty acids excretion in feces (mg per day) was observed in the LipiGO group compared with the negative control group (747.45 vs 440.82 g/day) (Figure 1). HDL/total cholesterol ratio was also ameliorated in the LipiGO group compared with the negative control group (0.16 vs 0.11).

A clinical trial was conducted including a total of 56 patients aged between 22-65 years with overweight or obesity type I defined as BMI>25 and <35 Kg m-2 were enrolled in a multi-centre, prospective, randomised, double-blind, placebo-controlled, parallel-group clinical trial. Treatment consisted in a daily consumption of 3 g of LipiGO for 12 weeks. The product was provided in delivery screw caps adaptable to liquid bottles. Each subject distributed the consumption with main mails. Compared with baseline values, change in body weight was reduced in 1.1 ffl 0.8 kg in LipiGO group resulting in a body weight difference of 2.6 kg compared with placebo ($P = 0.003$) (Figure 1). Waist perimeter was also reduced in LipiGO group in 1,5 cm ($P = 0.03$) whereas it was not significantly altered in placebo group.